The Center for Aquaculture Technologies on Prince Edward Island is one of two CAT facilities. Photo: CAT

AquaBounty teams up to ensure salmon sterility

Transgenic salmon producer AquaBounty has signed a licensing and research agreement with the Center for Aquaculture Technologies (CAT) to employ CAT’s patented sterility technology for use in products developed by AquaBounty.

Published Last updated

The companies are co-funding CAT’s research using gene editing to produce a sterile finfish for use in aquaculture. CAT will hold the patents and AquaBounty will receive a non-exclusive, royalty-free, licence to those patents and the technology. The development work will be performed at CAT’s facility in San Diego.

Dr John Buchanan, chief executive of CAT and a former R&D director at AquaBounty, said in a press release: “We are delighted to work with AquaBounty to develop this technology and realise its potential in aquaculture.”

Ronald Stotish: Project has a broad range of potential applications.

Many benefits

AquaBounty chief executive Ronald Stotish said: “Although AquaBounty has been very successful in routinely achieving levels approaching 100% sterility using triploid induction technology, we are very pleased to be working with CAT and using their innovative gene editing approach to ensure 100% sterility genetically.

“Sterility of farmed fish has many environmental and production benefits and we believe this project has a broad range of potential applications in the industry.”

CAT is a leading aquaculture R&D company focused on improving productivity, efficiency and sustainability in the aquaculture industry.

It operates two laboratories: its research hub in San Diego, California, and the world’s only Level 3 certified pathogen containment, private aquaculture research facility located on Prince Edward Island in Canada. AquaBounty also has R&D premises at Rollo Bay on Prince Edward island and is building a 250-tonne grow-out facility there.